

Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED

Statement of Profit and Loss for the period ended 30th September, 2017

Rs. in lakhs

	Particulars	Note No.	Qtr. Ended Unaudited 30.09.2017	Qtr. Ended Audited 30.06.2017	Qtr. Ended Unaudited 30.09.2016	Year to date figures for current period ended 30.9.2017	Year to date figures for previous period ended 30.9.2016	Year Ended Audited 31.03.2017
I	Revenue From Operations		4.90	19.58	31.18	24.48	65.38	120.25
II	Other Income		0.40	-	-	0.40	0.04	1.01
III	Total Income (I+II)		5.30	19.58	31.18	24.88	65.42	121.26
IV	EXPENSES							
	Cost of materials consumed		-	2.67	1.29	2.67	4.48	64.49
	Purchases of Stock-in-Trade		4.50	2.63	14.41	7.13	24.64	-
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress		(0.52)	21.19	(0.73)	20.67	7.22	2.95
	Employee benefits expense		1.62	3.51	5.48	5.13	11.46	16.63
	Finance costs		0.03	0.02	1.48	0.05	2.85	4.01
	Depreciation and amortization expense		0.02	-	1.96	0.02	3.92	6.37
	Other expenses		6.88	7.98	12.09	14.86	17.50	70.53
	Total expenses (IV)		12.53	38.00	35.98	50.53	72.07	164.98
V	Profit/(loss) before exceptional items and tax (III- IV)		(7.23)	(18.42)	(4.80)	(25.65)	(6.65)	(43.72)
VI	Exceptional Items				-	-	-	51.97
VII	Profit/(loss) before tax (V+VI)		(7.23)	(18.42)	(4.80)	(25.65)	(6.65)	8.25
VIII	Tax expense:							
	(1) Current tax Adj. of earlier year		1.75	-	-	1.75	-	-
	(2) Deferred tax		-	-	-	-	-	(2.72)
IX	Profit (Loss) for the period from continuing operations (VII-VIII)		(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
X	Profit/(loss) from discontinued operations		-	-	-	-	-	-
XI	Tax expense of discontinued operations		-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)		(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
XIV	Other Comprehensive Income		-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss		-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss		-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		-	-	-	-	-	-
XVI	Earnings per equity share (for continuing operation):		-	-	-	-	-	-
	(1) Basic		(0.26)	(0.54)	(0.14)	(0.80)	(0.20)	0.32
	(2) Diluted		(0.26)	(0.54)	(0.14)	(0.80)	(0.20)	0.32
XVII	Earnings per equity share (for discontinued operation):							
	(1) Basic							
	(2) Diluted							
XVII	Earnings per equity share (for discontinued & continuing operations)							
	(1) Basic							
	(2) Diluted							



Directors of the Company at their meeting

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors held on 15th November, 2017. 2. The Un-Audited Financial Results for the Quarter ended 30th Sept, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only 5) Provision for Income Tax and Deferred Tax will be made at the end of the Financial year.

Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30 June 2017 and year ended 31 March 2017 is as follows:

Particulars	Quarter Ended			Six months Ended		Year ended
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net profit reported for the quarter earlier as per the previous Indian GAAP	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
Net profit for the period as per Ind AS	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
Other Comprehensive Income	-	-	-	-	-	-
Total Comprehensive Income for the period as per Ind AS	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97

For PHARMAIDS PHARMACEUTICALS LIMITED

For Pharmaids Pharmaceuticals Limited

DR. GHISULAL JAIN

MANAGING DIRECTOR

Managing Director

Place : Hyderabad

Date : 15-11-2017

Vide our Report of 15/11/17

**For RAKESH S. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS**

B. Ramesh Kumar
(B. RAMESH KUMAR)
PARTNER
M.No: 200304

Name of the Company **PHARMAIDS PHARMACEUTICALS LIMITED**
 Balance Sheet as at 30th September 2017

(Rs in Lakhs)

Particulars	Note No.	Figures as at the end of	Figures as at the end of
		30.09.2017	31.03.2017
1	2	3	4
1 ASSETS			
Non-current assets		0.31	-
(a) Property, Plant and Equipment		-	-
(b) Capital work-in-progress		-	-
(c) Investment Property		-	-
(d) Goodwill		-	-
(e) Other Intangible assets		-	-
(f) Intangible assets under development		-	-
(g) Biological Assets other than bearer plants		-	-
(h) Financial Assets		-	-
(i) Investments		-	-
(ii) Trade receivables		-	-
(iii) Loans		-	-
(iv) Others (to be specified)		-	-
(i) Deferred tax assets (net)		34.67	37.95
(j) Other non-current assets		-	-
2 Current assets		1.12	24.46
(a) Inventories		-	-
(b) Financial Assets		-	-
(i) Investments		62.37	78.77
(ii) Trade receivables		19.29	8.17
(iii) Cash and cash equivalents		33.38	52.70
(iv) Bank balances other than (iii) above		-	-
(v) Loans		-	-
(vi) Others (to be specified)		-	-
(c) Current Tax Assets (Net)		-	-
(d) Other current assets		-	-
Total Assets		151.14	202.05
EQUITY AND LIABILITIES Equity		336.31	336.31
(a) Equity Share capital		(220.93)	(193.53)
(b) Other Equity		-	-
LIABILITIES			
1 Non-current liabilities			
(a) Financial Liabilities		9.26	9.26
(i) Borrowings		-	-
(ii) Trade payables		-	-
(iii) Other financial liabilities (other than those specified in item (b), to be specified)		-	-
(b) Provisions		-	-
(c) Deferred tax liabilities (Net)		-	-
(d) Other non-current liabilities		-	-
2 Current liabilities			
(a) Financial Liabilities		2.65	2.65
(i) Borrowings		23.24	44.78
(ii) Trade payables		-	-
(iii) Other financial liabilities (other than those specified in item (c))		-	-